India Cardiac Biomarkers Market Research Report By Type (Creatine Kinase (CK-MB), Troponins T, Imyoglobin, BNPs, IMA, Others), By Location of Testing (Point of Care, Laboratory Testing) and By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis)-Forecast to 2035

India Cardiac Biomarkers Market Overview

As per MRFR analysis, the India Cardiac Biomarkers Market Size was estimated at 0.86 (USD Billion) in 2023. The India Cardiac Biomarkers Market Industry is expected to grow from 1.2(USD Billion) in 2024 to 4 (USD Billion) by 2035. The India Cardiac Biomarkers Market CAGR (growth rate) is expected to be around 11.567% during the forecast period (2025 - 2035).

Key India Cardiac Biomarkers Market Trends Highlighted

The India Cardiac Biomarkers Market is witnessing significant trends driven by the growing prevalence of cardiovascular diseases in the country. With an estimated rise in heart-related health issues, awareness programs aimed at early detection and preventive care are becoming increasingly important.
The Indian government has emphasized the necessity of cardiovascular health management, promoting health campaigns and research funding to address this public health challenge.
Moreover, the increasing integration of advanced technology in diagnostics is prompting healthcare facilities to adopt more efficient and accurate cardiac biomarkers, enhancing patient care.There are endless opportunities in India to cater to the also the diagnostic needs of the population.
The use of point-of-care testing devices could change how cardiac biomarkers are used in rural areas by allowing quick responses. Moreover, the collaboration of diagnostic labs with pharmaceutical companies to create new biomarker tests further opens up the market. There has been a recent shift towards personalized medicine, which uses genetic and biochemical data to create individualized treatment regimens.

This shift is particularly relevant in the Indian context, where diverse genetic backgrounds can influence disease manifestations and responses to treatments. Furthermore, a growing focus on holistic healthcare systems encourages partnerships between conventional medicine and traditional practices, giving rise to integrative health strategies.
Collectively, these trends signal a dynamic and evolving landscape in the India Cardiac Biomarkers Market, poised for growth in response to both healthcare challenges and technological advancements.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

India Cardiac Biomarkers Market Drivers

Growing Prevalence of Cardiovascular Diseases

India is experiencing a significant rise in cardiovascular diseases (CVDs), which is a primary driver for the India Cardiac Biomarkers Market. According to the Indian Heart Association, CVDs are projected to become the leading cause of death in India, with an estimated 1.6 million deaths occurring annually.
This alarming statistic highlights the urgent need for effective diagnostic tools such as cardiac biomarkers, which can aid in early detection, monitoring, and management of heart conditions.
Organizations such as the All India Institute of Medical Sciences (AIIMS) and the cardiology departments of numerous hospitals are advocating for the enhanced use of cardiac biomarkers in clinical practice to combat this public health crisis. The increasing burden of CVD provides a compelling case for investment in cardiac biomarker research and development, ultimately driving market growth in the coming years.

Advancements in Diagnostic Technology

Technological advancements in the field of diagnostics are another significant driver for the India Cardiac Biomarkers Market. The introduction of point-of-care testing devices allows for rapid and accurate measurement of cardiac biomarkers at the patient’s bedside.
The Indian government has been actively promoting the adoption of innovative diagnostic technologies under initiatives such as 'Make in India.' With organizations like the Indian Council of Medical Research (ICMR) supporting the creation and distribution of advanced cardiac testing kits, this trend indicates a growing acceptance of new technologies, which can facilitate quicker diagnosis and treatment initiatives.
Furthermore, the growing prevalence of telemedicine during and after the COVID-19 pandemic is increasing the demand for remote monitoring and diagnostic tools, thereby augmenting the cardiac biomarkers market.

Increased Government and Private Investment in Healthcare

The Indian government has significantly increased its focus on healthcare investment, especially in the realm of Non-Communicable Diseases (NCDs) like cardiovascular ailments. Initiatives such as the National Health Mission and the Ayushman Bharat scheme aim to improve healthcare infrastructure and access to quality diagnostics across the nation.
This renewed emphasis on fighting NCDs, coupled with private sector investments, is vital for the development and promotion of cardiac biomarkers.Notably, collaborations between public entities and private companies, like the partnership between the Drug Controller General of India and various biotech firms, have spurred innovation and clinical trials in the cardiac biomarker sector, ensuring that advanced testing methods are brought to market swiftly. This is a crucial element in increasing availability and access to cardiac diagnostics across diverse demographics, thus buoying market growth.

Rising Awareness about Preventive Healthcare

There is a noticeable uptick in awareness regarding preventive healthcare among the Indian population, particularly with regard to heart health. The Ministry of Health and Family Welfare has been actively conducting campaigns emphasizing the importance of early detection of heart diseases through diagnostic tests.
Public awareness programs, supported by organizations like the Heart Care Foundation of India, are instrumental in educating the populace on the role of cardiac biomarkers in preventive healthcare.
According to recent surveys, there has been a 30% increase in individuals seeking regular health check-ups that integrate cardiac biomarker testing over the last five years. This heightened awareness drives demand for cardiovascular diagnostics, subsequently propelling growth in the India Cardiac Biomarkers Market.

India Cardiac Biomarkers Market Segment Insights

Cardiac Biomarkers Market Type Insights

The India Cardiac Biomarkers Market is currently segmented into various types that play a crucial role in the diagnosis and management of cardiovascular diseases. Among these, Creatine Kinase MB (CK-MB) is a notable biomarker, primarily used for its specificity to heart injury, making it a vital tool in acute myocardial infarction diagnosis. The Troponins T is recognized as one of the most sensitive and specific markers for myocardial injury, thus dominating the diagnostic landscape in clinical settings.
Myoglobin, while less specific than troponins, serves as an early indicator of heart damage due to its quick release into the bloodstream following myocardial injury.BNPs (B-type Natriuretic Peptides) are instrumental in heart failure management, providing critical insights into the severity of heart failure and guiding therapeutic strategies.
IMA (Ischemia-Modified Albumin) is gaining relevance as a novel biomarker due to its potential to indicate ischemia, thus aiding in the early detection of cardiac conditions. Moreover, the 'Others' category encompasses various emerging biomarkers that are under research and development, reflecting the ongoing innovation in this field. The rising incidence of cardiac diseases in India, coupled with an increasing population of elderly individuals, is propelling the demand for these biomarkers in clinical settings.
This trend is further supported by advancements in healthcare infrastructure and increased awareness about heart diseases among the population, which are driving factors in the growth of the India Cardiac Biomarkers Market.
The segmentation of this market into specific types is significant as it allows healthcare professionals to tailor their diagnostic and treatment approaches based on specific biomarkers, ultimately resulting in improved patient outcomes. With the ongoing focus on enhancing diagnostic precision and treatment efficacy, the future of these biomarkers in the India Cardiac Biomarkers Market appears promising.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Cardiac Biomarkers Market Location of Testing Insights

The India Cardiac Biomarkers Market, particularly the Location of Testing segment, plays a crucial role in the early detection and management of cardiovascular diseases, which are a leading cause of mortality in the country. The market is largely driven by the growing prevalence of heart disease and the increasing demand for rapid diagnostic solutions. Among the various options, Point of Care testing has gained significant traction due to its ability to deliver immediate results, empowering healthcare providers to make prompt treatment decisions.
This segment appeals to patients and healthcare facilities looking for convenience and efficiency, particularly in emergency settings. On the other hand, Laboratory Testing remains an essential aspect of the market, providing comprehensive analysis and a thorough understanding of complex cardiac conditions. This method is often preferred in clinical settings where accuracy and in-depth results are critical for patient management.
Both Point of Care and Laboratory Testing are vital, with their unique advantages addressing the diverse needs of the population. Government initiatives aimed at enhancing healthcare infrastructure and increasing awareness about cardiovascular diseases are expected to further support growth in these areas, ultimately contributing to improved health outcomes in India. With the ongoing advances in technology and supportive policies, the India Cardiac Biomarkers Market is positioned to witness continuous evolution, reflecting the growing need for reliable and efficient testing solutions.

Cardiac Biomarkers Market Application Insights

The Application segment of the India Cardiac Biomarkers Market plays a crucial role in the early diagnosis and management of cardiovascular diseases, which are a leading cause of mortality in India. Conditions like Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Atherosclerosis constitute a significant burden on healthcare systems.
Each of these applications leverages specific biomarkers to enhance diagnostic accuracy, facilitate timely intervention, and improve patient outcomes. Myocardial Infarction currently dominates the landscape due to its high prevalence, necessitating rapid detection methods to reduce fatality rates.Similarly, Congestive Heart Failure exhibits a growing incidence rate linked to aging populations and lifestyle factors, signaling a vital need for effective monitoring through cardiac biomarkers.
Furthermore, Acute Coronary Syndrome presents challenges in timely diagnosis, making biomarkers instrumental in differentiating between unstable angina and myocardial infarction.
Lastly, Atherosclerosis serves as an underlying risk factor for various cardiovascular diseases, heightening the importance of identifying biomarkers associated with this condition.The increasing awareness of cardiovascular health, coupled with advancements in diagnostic technologies, is projected to drive significant growth and innovation in these applications, highlighting their importance in the India Cardiac Biomarkers Market.

India Cardiac Biomarkers Market Key Players and Competitive Insights

The India Cardiac Biomarkers Market is emerging as a critical segment within the healthcare industry, addressing the pressing need for advanced diagnostics tools to effectively detect and manage cardiovascular diseases. With the rising prevalence of heart-related ailments in the country, the market is witnessing increased investment and innovation from various stakeholders, including manufacturers, research institutions, and healthcare providers. Competitive insights into this market highlight the ongoing advancements in technology, regulatory developments, and the focus on tailored solutions that can enhance patient outcomes.
As the demand for accurate and rapid diagnostic testing continues to grow, the competitive landscape is characterized by a dynamic interplay of established players and new entrants, each striving to capture significant market share by developing innovative products and expanding their service networks.Siemens Healthineers stands out as a significant competitor within the India Cardiac Biomarkers Market, leveraging its extensive portfolio of diagnostic imaging and laboratory solutions.
The company is recognized for its commitment to improving patient care through innovative technologies and diagnostic capabilities. Siemens Healthineers offers a range of cardiac biomarkers that facilitate the timely assessment of cardiac conditions, enhancing the speed and accuracy of diagnostics in clinical settings. Its strong presence in India is strengthened by strategic partnerships with healthcare institutions and a robust distribution network.
Furthermore, the company's focus on continuous research and development allows it to introduce cutting-edge solutions tailored to the specific needs of the Indian healthcare landscape, thereby reinforcing its position in the market and ensuring higher standards of cardiac care.Bristol-Myers Squibb has made significant strides within the India Cardiac Biomarkers Market by focusing on the development and commercialization of innovative therapeutic solutions alongside diagnostics.
The company aims to address unmet medical needs in cardiovascular health, particularly in offering targeted therapies that can complement the testing and interpretation of cardiac biomarkers. Bristol-Myers Squibb's presence in India has been marked by key collaborations and partnerships that enhance its market footprint while expanding access to critical products.
The company's strength lies in its comprehensive understanding of the cardiac care ecosystem, allowing it to align its offerings with the evolving demands of healthcare professionals and patients. Bristol-Myers Squibb has also been involved in various mergers and acquisitions, strategically positioning itself to enhance its service offerings and technological capabilities within the cardiovascular segment in India, further contributing to the robust growth of the cardiac biomarkers market.

Key Companies in the India Cardiac Biomarkers Market Include

• Siemens Healthineers


• Bristol-Myers Squibb


• Abbott Laboratories


• Beckman Coulter


• Evoke Pharma


• BioRad Laboratories


• Daxor Corporation


• Ortho Clinical Diagnostics


• Roche


• Cardiorentis


• Thermo Fisher Scientific


• Randox Laboratories


• Quidel Corporation

India Cardiac Biomarkers Market Industry Developments

The India Cardiac Biomarkers Market has seen significant developments in recent months, particularly in technological advancements and corporate activities. Companies such as Siemens Healthineers and Abbott Laboratories have ramped up their product offerings, introducing innovative diagnostic solutions to cater to the rising prevalence of cardiovascular diseases in India.
Recent growth in market valuation is largely credited to the increasing demand for rapid diagnostic tests, particularly amidst the ongoing public health focus on heart-related ailments. Notably, in March 2023, Roche announced a partnership with a local Indian entity to enhance its distribution network. Furthermore, in January 2023, Bristol-Myers Squibb expanded its research initiatives in India, aiming to develop pioneering cardiac therapies.
The competitive landscape also indicates potential mergers and acquisitions; for instance, discussions around a strategic partnership between Randox Laboratories and Daxor Corporation were reported in September 2023, focusing on enhancing biomarker testing capabilities.
Over the last few years, the Indian government has also actively promoted healthcare initiatives, increasing investment in cardiac care infrastructure, thereby fostering a favorable environment for market growth and innovation within the cardiac biomarkers sector.

India Cardiac Biomarkers Market Segmentation Insights

Cardiac Biomarkers Market Type Outlook

• Creatine Kinase (CK-MB)


• Troponins T


• Imyoglobin


• BNPs


• IMA


• Others

Cardiac Biomarkers Market Location of Testing Outlook

• Point of Care


• Laboratory Testing

Cardiac Biomarkers Market Application Outlook

• Myocardial Infarction


• Congestive Heart Failure


• Acute Coronary Syndrome


• Atherosclerosis

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	0.86(USD Billion)
MARKET SIZE 2024	1.2(USD Billion)
MARKET SIZE 2035	4.0(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	11.567% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Siemens Healthineers, BristolMyers Squibb, Abbott Laboratories, Beckman Coulter, Evoke Pharma, BioRad Laboratories, Daxor Corporation, Ortho Clinical Diagnostics, Roche, Cardiorentis, Thermo Fisher Scientific, Randox Laboratories, Quidel Corporation
SEGMENTS COVERED	Type, Location of Testing, Application
KEY MARKET OPPORTUNITIES	Increasing prevalence of cardiovascular diseases, Growing demand for rapid diagnostic tests, Advancement in biomarker technologies, Government support for healthcare innovations, Rising awareness of preventive healthcare
KEY MARKET DYNAMICS	increasing cardiovascular diseases prevalence, rising aging population, advancements in diagnostic technologies, growing awareness and health expenditure, government initiatives and funding
COUNTRIES COVERED	India